leisure time -WSS

leisure time

author：focus 2025-09-29 23:27:49 - browse：874

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： How dance can help health care workers heal from trauma

WSS

Time to name cancers by genetics, not organ of origin, expert says

Some dementia cases could be undiagnosed liver disease

FDA drug safety: Singulair case shows systemic surveillance flaws

Do digital therapeutics have a future in medicine?

DOJ, FTC to increase scrutiny of all types of health care mergers

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

hotspot

leisure time

hotspot

Medical records are filled with copy

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Dobbs anniversary: the lost opportunity of abortion as health care

Stanford updates investigation of president’s past research

The high cost of giving birth even with insurance

Commercial surrogacy can be ethical, despite pope’s claims

Moonlake's readout produced a cash windfall. Risks remain

Even great ERs can’t make up for American health disparities

In Memoriam: Notable people who died in 2023

The lessons of Aduhelm, an Alzheimer's drug that was not to be

hotspot

FDA drug safety: Singulair case shows systemic surveillance flaws

Lindsay Lohan welcomes 1st child with husband Bader Shammas

A $475,000 price tag for a new cancer drug: crazy or meh?

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Vertigo drug brings hope for rare neuron disorder, Niemann

entertainment

knowledge

Wikipedia

entertainment